Immatics Unveils IMA203CD8 Phase 1a Findings Demonstrating Durable Responses And Tumor-Agnostic Potential In PRAME-Expressing Cancers

2025-12-11 20:11

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalation
Manageable tolerability across all dose levels
Encouraging early clinical anti-tumor activity in advanced solid tumors after one-time infusion of IMA203CD8 at a low median dose during ongoing dose escalation, including deep and durable responses
Promising dose-dependent clinical signal in ovarian carcinoma supports the strategy to position IMA203CD8 in the tumor-agnostic setting of advanced PRAME cancers beyond melanoma, starting with gynecologic cancers
Dose escalation and determination of RP2D on track to be completed in 2026, including data on two highest dose levels